[{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chiome Bioscience \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Asahi Kasei Pharma"}]

Find Immunology Clinical Drug Pipeline Developments & Deals by Chiome Bioscience

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Europe
                          Not Confirmed
                          ISPE Europe
                          Not Confirmed

                          Details : Under the licensing agreement, Asahi Kasei Pharma has acquired worldwide exclusive rights to develop and commercialize PFKR an anti-CX3CR1 antibody from Chiome.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 20, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Asahi Kasei Pharma

                          Deal Size : $163.5 million

                          Deal Type : Licensing Agreement

                          blank